Plain-English translation of NCT06617325 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a study testing dapirolizumab pegol as an add-on treatment for moderate to severe systemic lupus erythematosus (SLE), a condition where your immune system mistakenly attacks your body's own tissues. The medication is designed to work alongside the treatments you're already taking. The study will compare how well people do when they receive this medication versus a placebo (a fake treatment), to see if it helps control your lupus symptoms better over time.
Many people with lupus continue to have flares and active disease even when taking standard medications. This trial exists to find out whether this medication can help reduce those flares and give people better long-term control of their disease.
You likely qualify if…
You likely don't qualify if…
If you join this study, you'll continue taking your current lupus medications while also receiving either the new medication or a placebo throughout the treatment period. You'll attend regular clinic visits so the research team can monitor how you're doing through blood tests, physical exams, and questionnaires that measure your lupus activity. The study involves about 450 participants across multiple centers, and you'll be randomly assigned to receive either the medication or placebo so researchers can fairly compare how well the treatment works.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
United States